ClinicalTrials.gg
RecruitingNCT06740188n-REMSSUpdated Feb 19, 2025

Trazodone on NREM Sleep Stage Ⅲ in Depressed Insomniac Co-morbid Patients

A Phase 4 interventional study of 5-hydroxytryptamine balanced antidepressants trazodone and Citalopram hydrobromide combined with zolpidem in Depressed Insomniac Co-morbid Patients, sponsored by Tongji University. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Tongji University · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 358 studies in Depression with a site in China — 119 open to participants now, 138 under way, 3 of them phase 3. Depression · China.

Planned enrollment
212th of 284
60 · median 129
Started
2025
with 40 others
Phase 4
24 of 358
10 open now
Primary completion
2026-12
later than 79 of 137 live
Registered
260th of 358
by date

Among the 358 studies in Depression with a site in China, this one is the 212th largest by planned enrollment of the 284 interventional ones that give a count, is one of 41 that started in 2025, is one of 24 in phase 4, reaches primary completion later than 79 of the 137 other live ones, and was the 260th registered.

Depression

8,602 studies on the registry are indexed under Depression; 1,735 are open to participants now.

Browse Depression studies →

Open to participants now

119 of the 358 studies in Depression with a site in China are open now. Recruiting first, the newest first:

114 more — sign in →

All 119 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,099 Depression studies recruiting now, 474 (43%) set no upper age limit and 524 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 358 studies in Depression with a site in China, or all of them as a file.
02

Study summary

This study used polysomnographic technology and randomly selected 60 patients who met the diagnostic criteria for depression and non-organic insomnia as stipulated in DSM-5 into an intervention group (n=30) and a control group (n=30). The intervention group was given only 5-hydroxytryptamine balanced antidepressants trazodone, while the control group was given citalopram hydrobromide combined with zolpidem. Both groups underwent PSG at baseline and 1 week after medication, and were assessed with the 17-item Hamilton Depression Rating Scale, Zung Self-Rating Depression Scale, Pittsburgh Sleep Quality Index, Arnsworth Insomnia Severity Scale, Antidepressant Side Effects Checklist, and the Drug Dependence Scale neuropsychological assessment at baseline, 1, 2, and 4 weeks after medication. The study aimed to explore the effects of single use of SMAs class antidepressants versus combination with other antidepressants on non-rapid eye movement sleep stage III in patients with depression and insomnia comorbidity, and to compare the effects of depression and insomnia in the two groups.

03

Conditions studied

  • Depressed Insomniac Co-morbid Patients

Keywords

  • Trazodone
  • Non-rapid Eye Movement Sleep Stage
  • depression
  • insomnia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatient or inpatient patients;
  • 18 years old ≤ 65 years old;
  • Simultaneously meet the diagnostic criteria for depression and non organic insomnia in the fifth edition of the (DSM-5) in the United States;
  • 17 items of Hamilton Depression Rating Scale (HAMD-17) with a total score of ≥ 17 points;
  • Pittsburgh Sleep Quality Index (PSQI) ≥ 16 points;
  • Never used related antidepressants and sedative hypnotic drugs;
  • Has a certain level of visual and auditory resolution, and no comprehension barriers;
  • Capable of independently completing scale measurements;
  • Education level above primary school;
  • Obtain written from the patient, and obtain written informed consent from the legal guardian if the patient is incapacitated during the onset of the illness.

Exclusion criteria

Exclusion Criteria:

  • Patients with comorbidities such as schizophrenia, schizophrenia, bipolar disorder, mental retardation, pervasive developmental disorder, delirium, dementia, cognitive impairment, alcohol dependence, etc
  • Suffering from serious organic diseases, such as diabetes, thyroid disease, hypertension, cardiovascular disease, craniocerebral trauma, cerebral ischemia or hemorrhage;
  • Patients with narrow angle glaucoma;
  • History of epilepsy and febrile seizures;
  • Individuals with a history of drug use;
  • Positive for syphilis specific antibody and AIDS antibody;
  • According to risk assessment, there are currently serious suicide attempts or individuals who are overly agitated Pregnant or lactating women, or those planning to conceive in the near future;
  • Laboratory tests indicate the presence of liver and kidney function impairment in individuals;
  • There are other individuals who meet the relevant for antidepressants.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Intervention group

    The intervention group was given only 5-hydroxytryptamine balanced antidepressants trazodone.

    Drug: 5-hydroxytryptamine balanced antidepressants trazodone

  • Active comparator
    Control group

    The control group was given citalopram hydrobromide combined with zolpidem.

    Drug: Citalopram hydrobromide combined with zolpidem

Interventions

  • Drug5-hydroxytryptamine balanced antidepressants trazodone

    The intervention group was given only 5-hydroxytryptamine balanced antidepressants trazodone

  • DrugCitalopram hydrobromide combined with zolpidem

    Drug pages: CitalopramStudies of CitalopramCitalopram pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ZolpidemStudies of ZolpidemZolpidem pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    the control group was given citalopram hydrobromide combined with zolpidem

06

What researchers measure

Primary outcomes

  1. Sleep structure staging

    Monitoring sleep structure staging through Polysomnography(PSG): W period (awake period): Refers to the time when one has not entered a sleep state; N1 stage (non rapid eye movement stage 1): light sleep stage, accounting for about 5-10%; N2 stage (non rapid eye movement stage 2): The main part of sleep, accounting for about 50%; N3 stage (non rapid eye movement stage 3): Deep sleep stage, accounting for about 20%, is crucial for memory consolidation and recovery; R phase (rapid eye movement phase): related to dreams, accounting for about 20-25%.

    Time frame: Baseline and 1 week after medication

Secondary outcomes

  1. The 17 item Hamilton Depression Scale (HAMD-17)

    The 17 item Hamilton Depression Scale (HAMD-17) evaluates the severity of depression and treatment outcomes in patients. Composed of 17 items, ranging from 7 to 13 points, it is classified as mild depression; 14-19 points are classified as moderate depression; ≥ 20 points is classified as severe or above.

    Time frame: baseline, 1, 2, and 4 weeks after medication

  2. Zong's Self rating Depression Scale (SDS)

    Zong's Self rating Depression Scale (SDS): It can intuitively reflect the subjective feelings of depressed patients and their symptom changes during treatment. Composed of 20 items, the severity is rated on a 4-point scale from 1 to 4, with 53-62 indicating mild depression, 63-72 indicating moderate depression, and ≥ 72 indicating severe depression.

    Time frame: baseline, 1, 2, and 4 weeks after medication

  3. The Pittsburgh Sleep Quality Index (PSQI)

    The Pittsburgh Sleep Quality Index (PSQI) evaluates a patient's sleep quality over the past month, including sleep outcomes and duration. There are a total of 18 items and 7 dimensions, each item is rated on a 4-point scale from 0 to 3. The higher the score, the worse the sleep quality.

    Time frame: baseline, 1, 2, and 4 weeks after medication

  4. The Athens Insomnia Scale (AIS)

    The Athens Insomnia Scale (AIS) can be used as a subjective evaluation of insomnia in patients. Composed of 8 items, the severity is evaluated using a 4-point scale from 0 to 3, with a total score range of 0 to 24 points. The higher the score, the worse the sleep quality.

    Time frame: baseline, 1, 2, and 4 weeks after medication

  5. The Antidepressant Side Effect Checklist (ASEC)

    The Antidepressant Side Effect Checklist (ASEC) evaluates the adverse reactions of patients after using antidepressants, including physical fatigue, dizziness, headache, sleep disturbances, erectile dysfunction, palpitations, tremors, sweating, dry mouth, constipation, urinary disorders, drowsiness, sexual dysfunction, and other symptoms. Composed of 21 items, the severity is evaluated using a 4-point scale from 0 to 3, with higher scores indicating more severe side effects. evaluates the adverse reactions of patients after using antidepressants, including physical fatigue, dizziness, headache, sleep disturbances, erectile dysfunction, palpitations, tremors, sweating, dry mouth, constipation, urinary disorders, drowsiness, sexual dysfunction, and other symptoms. Composed of 21 items, the severity is evaluated using a 4-point scale from 0 to 3, with higher scores indicating more severe side effects.

    Time frame: baseline, 1, 2, and 4 weeks after medication

  6. Drug Dependence Scale (DDS)

    Drug Dependence Scale (DDS) used to identify the degree of drug use dependence. This scale adopts a 4-point rating system, with higher scores indicating higher levels of drug dependence.

    Time frame: baseline, 1, 2, and 4 weeks after medication

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Geyer JD, Carney PR, Dillard SC, Davis L, Ward LC. Antidepressant medications, neuroleptics, and prominent eye movements during NREM sleep. J Clin Neurophysiol. 2009 Feb;26(1):39-44. doi: 10.1097/WNP.0b013e318196046f. PubMed 19151617 ↗
  • Sheehan DV, Rozova A, Gossen ER, Gibertini M. The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder. Psychopharmacol Bull. 2009;42(4):5-22. PubMed 20581790 ↗
  • Sheehan DV, Croft HA, Gossen ER, Levitt RJ, Brulle C, Bouchard S, Rozova A. Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study. Psychiatry (Edgmont). 2009 May;6(5):20-33. PubMed 19724732 ↗
  • Roth AJ, McCall WV, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. J Sleep Res. 2011 Dec;20(4):552-8. doi: 10.1111/j.1365-2869.2011.00928.x. Epub 2011 May 30. PubMed 21623982 ↗
  • Jarema M, Dudek D, Landowski J, Heitzman J, Rabe-Jablonska J, Rybakowski J. [Trazodon--the antidepressant: mechanism of action and its position in the treatment of depression]. Psychiatr Pol. 2011 Jul-Aug;45(4):611-25. Polish. PubMed 22232986 ↗
  • Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS; Scientific Advisory Board and the Executive Committee of the Grand Challenges on Global Mental Health; Anderson W, Dhansay MA, Phillips A, Shurin S, Walport M, Ewart W, Savill SJ, Bordin IA, Costello EJ, Durkin M, Fairburn C, Glass RI, Hall W, Huang Y, Hyman SE, Jamison K, Kaaya S, Kapur S, Kleinman A, Ogunniyi A, Otero-Ojeda A, Poo MM, Ravindranath V, Sahakian BJ, Saxena S, Singer PA, Stein DJ. Grand challenges in global mental health. Nature. 2011 Jul 6;475(7354):27-30. doi: 10.1038/475027a. No abstract available. PubMed 21734685 ↗

Individual participant data

Plan to share: Yes

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

Of 110 non-industry phase 4 interventional studies under Depression, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's planned 23 months is below that.

Counting every sponsor, half of 119 studies reached it within 32 months; a quarter within 17 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2024
First posted
Dec 18, 2024
StartActual
Jan 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06740188
Lead sponsor
Tongji University
Responsible party
Jie Tong (Prof., Tongji University) — Principal investigator
First posted
Dec 18, 2024
Start date
Jan 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 19, 2025

Study contacts

Meiling Liu, M.M.
Contact
tongjie_room@126.com
86+2168306699

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion